Pharmaceutical immunoglobulins reduce neutrophil extracellular trap formation and ameliorate the development of MPO-ANCA-associated vasculitis

References

• Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16(2):R101.
   PubMed Web of Science ®Google Scholar
• Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22(3):394–404.
   PubMed Web of Science ®Google Scholar
• Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306–9.
   PubMed Web of Science ®Google Scholar
• Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–94.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10(8):463–73.
   PubMed Web of Science ®Google Scholar
• Kallenberg CG. Advances in pathogenesis and treatment of ANCA-associated vasculitis. Discov Med. 2014;18(99):195–201.
   PubMed Web of Science ®Google Scholar
• Shillitoe B, Gennery A. X-linked agammaglobulinaemia: outcomes in the modern era. Clin Immunol. 2017;183:54–62.
   PubMed Web of Science ®Google Scholar
• Makatsori M, Kiani-Alikhan S, Manson AL, Verma N, Leandro M, Gurugama NP, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014;107(10):821–8.
   PubMed Web of Science ®Google Scholar
• Shah PJ, Vakil N, Kabakov A. Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. Am J Health Syst Pharm. 2015;72(12):1013–9.
   PubMed Web of Science ®Google Scholar
• Salama A. Emerging drugs for immune thrombocytopenia (ITP). Expert Opin Emerg Drugs. 2017;22(1):27–38.
   PubMed Web of Science ®Google Scholar
• Liu YC, Lin MT, Wang JK, Wu MH. State-of-the-art acute phase management of Kawasaki disease after 2017 scientific statement from the American Heart Association. Pediatr Neonatol. 2018;59(6):543–52.
   PubMed Web of Science ®Google Scholar
• Restrepo-Jimenez P, Rodriguez Y, Gonzalez P, Chang C, Gershwin ME, Anaya JM. The immunotherapy of Guillain-Barré syndrome. Expert Opin Biol Ther. 2018;18(6):619–31.
   PubMed Web of Science ®Google Scholar
• Koike H, Akiyama K, Saito T, Sobue G, Research Group for IVIg for EGPA/CSS in Japan. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J Neurol. 2015;262(3):752–9.
   PubMed Web of Science ®Google Scholar
• Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955–63.
   PubMed Web of Science ®Google Scholar
• Soderberg D, Segelmark M. Neutrophil extracellular traps in vasculitis, friend or foe? Curr Opin Rheumatol. 2018;30(1):16–23.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.
   PubMed Web of Science ®Google Scholar
• Dabrowska D, Jablonska E, Garley M, Sawicka-Powierza J, Nowak K. The phenomenon of neutrophil extracellular traps in vascular diseases. Arch Immunol Ther Exp. 2018;66:273–81.
   PubMed Web of Science ®Google Scholar
• Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, Atsumi T, et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. JASN. 2014;25(5):990–7.
   Web of Science ®Google Scholar
• Nakazawa D, Tomaru U, Suzuki A, Yoshida M, Nishio S, Atsumi T, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3779–87.
   PubMed Web of Science ®Google Scholar
• Masuda S, Shimizu S, Matsuo J, Nishibata Y, Kusunoki Y, Hattanda F, et al. Measurement of NET formation in vitro and in vivo by flow cytometry. Cytometry A. 2017;91(8):822–9.
   PubMedGoogle Scholar
• Okubo K, Kamiya M, Urano Y, Nishi H, Herter JM, Mayadas T, et al. Lactoferrin suppresses neutrophil extracellular traps release in inflammation. EBioMedicine. 2016;10:204–15.
   PubMed Web of Science ®Google Scholar
• Shida H, Nakazawa D, Tateyama Y, Miyoshi A, Kusunoki Y, Hattanda F, et al. The presence of anti-lactoferrin antibodies in a subgroup of eosinophilic granulomatosis with polyangiitis patients and their possible contribution to enhancement of neutrophil extracellular trap formation. Front Immunol. 2016;7:636.
   PubMed Web of Science ®Google Scholar
• Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29(12):608–15.
   PubMed Web of Science ®Google Scholar
• Baerenwaldt A, Biburger M, Nimmerjahn F. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010;6(3):425–34.
   PubMed Web of Science ®Google Scholar
• Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127(2):315–23.
   PubMed Web of Science ®Google Scholar
• Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107(21):9813–8.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.
   PubMed Web of Science ®Google Scholar
• Kraaij T, Kamerling SWA, van Dam LS, Bakker JA, Bajema IM, Page T, et al. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. Kidney Int. 2018;94(1):139–49.
   PubMed Web of Science ®Google Scholar
• Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68(3):702–12.
   PubMed Web of Science ®Google Scholar
• Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000;93(7):433–9.
   PubMed Web of Science ®Google Scholar
• Teeling JL, De Groot ER, Eerenberg AJ, Bleeker WK, Van Mierlo G, Aarden LA, et al. Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro. Clin Exp Immunol. 1998;114(2):264–70.
   PubMed Web of Science ®Google Scholar